title: A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus.
abstract: OBJECTIVE
  The aim of this study was to compare the effectiveness of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with diabetes mellitus (DM).
  
  
  BACKGROUND
  Drug-eluting stent implantation significantly improved the angiographic and clinical outcomes compared with bare-metal stent implantation in diabetic patients. However, comparison of SES with PES in diabetic patients has not been sufficiently evaluated.
  
  
  METHODS
  This prospective, multicenter, randomized study compared SES (n = 200) and PES implantation (n = 200) for diabetic patients (n = 400). The primary end point was in-segment restenosis at 6 months according to intention-to-treat principle.
  
  
  RESULTS
  The 2 groups had similar baseline clinical and angiographic characteristics. Six-month in-stent (3.4% vs. 18.2%, p < 0.001) and in-segment restenosis (4.0% vs. 20.8%, p < 0.001) and 9-month target lesion revascularization (2.0% vs. 7.5%, p = 0.017) were significantly lower in the SES versus the PES group. The incidence of death (0% in SES vs. 0.5% in PES, p = 0.999) or myocardial infarction (0.5% in SES vs. 0.5% in PES, p = 0.999) at 9-month follow-up was not statistically different between the 2 groups. Major adverse cardiac events including death, myocardial infarction, and target lesion revascularization at 9 months (2.0% vs. 8.0%, p = 0.010) were lower in the SES versus the PES group.
  
  
  CONCLUSIONS
  Sirolimus-eluting stent implantation is superior in reducing angiographic restenosis and improving 9-month clinical outcomes in patients with DM and coronary artery disease compared with PES implantation.
authors: Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors: Seung-Whan
authors: SW
authors: Lee
authors: Seong-Wook
authors: SW
authors: Park
authors: Young-Hak
authors: YH
authors: Kim
authors: Sung-Cheol
authors: SC
authors: Yun
authors: Duk-Woo
authors: DW
authors: Park
authors: Cheol Whan
authors: CW
authors: Lee
authors: Myeong-Ki
authors: MK
authors: Hong
authors: Kyoung-Suk
authors: KS
authors: Rhee
authors: Jei Keon
authors: JK
authors: Chae
authors: Jae-Ki
authors: JK
authors: Ko
authors: Jae-Hyeong
authors: JH
authors: Park
authors: Jae-Hwan
authors: JH
authors: Lee
authors: Si Wan
authors: SW
authors: Choi
authors: Jin-Ok
authors: JO
authors: Jeong
authors: In-Whan
authors: IW
authors: Seong
authors: Yoon Haeng
authors: YH
authors: Cho
authors: Nae-Hee
authors: NH
authors: Lee
authors: June Hong
authors: JH
authors: Kim
authors: Kook-Jin
authors: KJ
authors: Chun
authors: Hyun-Sook
authors: HS
authors: Kim
authors: Seung-Jung
authors: SJ
authors: Park
mesh_terms: D000368:Aged; D019917:Blood Vessel Prosthesis Implantation; D015331:Cohort Studies; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D048909:Diabetes Complications / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011859:Radiography; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D050257:Tubulin Modulators; D017239:Paclitaxel; D020123:Sirolimus